175 related articles for article (PubMed ID: 33253260)
1. On the coherence of model-based dose-finding designs for drug combination trials.
Park Y; Liu S
PLoS One; 2020; 15(11):e0242561. PubMed ID: 33253260
[TBL] [Abstract][Full Text] [Related]
2. Beyond the 3+3 method: expanded algorithms for dose- escalation in Phase I oncology trials of two agents.
Braun TM; Alonzo TA
Clin Trials; 2011 Jun; 8(3):247-59. PubMed ID: 21730075
[TBL] [Abstract][Full Text] [Related]
3. Keyboard design for phase I drug-combination trials.
Pan H; Lin R; Zhou Y; Yuan Y
Contemp Clin Trials; 2020 May; 92():105972. PubMed ID: 32151751
[TBL] [Abstract][Full Text] [Related]
4. Randomized dose-escalation designs for drug combination cancer trials with immunotherapy.
Mozgunov P; Jaki T; Paoletti X
J Biopharm Stat; 2019; 29(2):359-377. PubMed ID: 30352007
[TBL] [Abstract][Full Text] [Related]
5. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
Guo B; Li Y
Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
[TBL] [Abstract][Full Text] [Related]
6. Two-stage approach based on zone and dose findings for two-agent combination Phase I/II trials.
Shimamura F; Hamada C; Matsui S; Hirakawa A
J Biopharm Stat; 2018; 28(6):1025-1037. PubMed ID: 29420127
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II adaptive design for drug combination oncology trials.
Wages NA; Conaway MR
Stat Med; 2014 May; 33(12):1990-2003. PubMed ID: 24470329
[TBL] [Abstract][Full Text] [Related]
8. Escalation with overdose control for phase I drug-combination trials.
Shi Y; Yin G
Stat Med; 2013 Nov; 32(25):4400-12. PubMed ID: 23630103
[TBL] [Abstract][Full Text] [Related]
9. Design issues in dose-finding Phase I trials for combinations of two agents.
Fan SK; Venook AP; Lu Y
J Biopharm Stat; 2009; 19(3):509-23. PubMed ID: 19384692
[TBL] [Abstract][Full Text] [Related]
10. Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control.
Tighiouart M; Piantadosi S; Rogatko A
Stat Med; 2014 Sep; 33(22):3815-29. PubMed ID: 24825779
[TBL] [Abstract][Full Text] [Related]
11. Applications of the partial-order continual reassessment method in the early development of treatment combinations.
Wages NA; Dillon PM; Portell CA; Slingluff CL; Petroni GR
Clin Trials; 2024 Jun; 21(3):331-339. PubMed ID: 38554038
[TBL] [Abstract][Full Text] [Related]
12. Competing designs for drug combination in phase I dose-finding clinical trials.
Riviere MK; Dubois F; Zohar S
Stat Med; 2015 Jan; 34(1):1-12. PubMed ID: 24464821
[TBL] [Abstract][Full Text] [Related]
13. A product of independent beta probabilities dose escalation design for dual-agent phase I trials.
Mander AP; Sweeting MJ
Stat Med; 2015 Apr; 34(8):1261-76. PubMed ID: 25630638
[TBL] [Abstract][Full Text] [Related]
14. CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method.
Bayar MA; Ivanova A; Le Teuff G
Comput Methods Programs Biomed; 2019 Jul; 176():211-223. PubMed ID: 31200907
[TBL] [Abstract][Full Text] [Related]
15. Designs for phase I trials in ordered groups.
Conaway MR; Wages NA
Stat Med; 2017 Jan; 36(2):254-265. PubMed ID: 27624880
[TBL] [Abstract][Full Text] [Related]
16. A Dose-Finding Method Based on Multiple Dosing in Two-Agent Combination Phase I Trials.
Kakurai Y; Hirakawa A; Hamada C
J Biopharm Stat; 2015; 25(5):1065-76. PubMed ID: 25369852
[TBL] [Abstract][Full Text] [Related]
17. Sequential or combined designs for Phase I/II clinical trials? A simulation study.
Rossoni C; Bardet A; Geoerger B; Paoletti X
Clin Trials; 2019 Dec; 16(6):635-644. PubMed ID: 31538815
[TBL] [Abstract][Full Text] [Related]
18. Bayesian adaptive linearization method for phase I drug combination trials with dimension reduction.
Pan H; Cheng C; Yuan Y
Pharm Stat; 2020 Sep; 19(5):561-582. PubMed ID: 32248647
[TBL] [Abstract][Full Text] [Related]
19. Adaptive designs for dual-agent phase I dose-escalation studies.
Harrington JA; Wheeler GM; Sweeting MJ; Mander AP; Jodrell DI
Nat Rev Clin Oncol; 2013 May; 10(5):277-88. PubMed ID: 23507740
[TBL] [Abstract][Full Text] [Related]
20. Methodologic guidelines for the design of high-dose chemotherapy regimens.
Margolin K; Synold T; Longmate J; Doroshow JH
Biol Blood Marrow Transplant; 2001; 7(8):414-32. PubMed ID: 11569887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
